The pharmacological studies of Yiqi Fumai lyophilized injection in cardiovascular system mainly include anti-cardiac failure,improvement of myocardial ischemia,improvement of myocardial hypertrophy and myocardial inju...The pharmacological studies of Yiqi Fumai lyophilized injection in cardiovascular system mainly include anti-cardiac failure,improvement of myocardial ischemia,improvement of myocardial hypertrophy and myocardial injury caused by ischemia and hypoxia.In recent years,a large number of studies have shown that Yiqi Fumai Lyophilized Injection has good protective effects on myocardial injury caused by ischemia and hypoxia by enhancing myocardial contractility and delaying ventricular remodeling.展开更多
Yi-Qi-Fu-Mai(YQFM) is extensively used clinically to treat cardiovascular diseases in China. To explore the anti-hypoxia effect of the extract of YQFM preparation(EYQFM), the EYQFM(1.4, 2.8, and 5.5 g·kg-1·d...Yi-Qi-Fu-Mai(YQFM) is extensively used clinically to treat cardiovascular diseases in China. To explore the anti-hypoxia effect of the extract of YQFM preparation(EYQFM), the EYQFM(1.4, 2.8, and 5.5 g·kg-1·d-1) was assessed for its heart-protective effect in a chronic intermittent hypoxia(CIH) animal model(oxygen pressure 7%-8%, 20 min per day) for 28 days of treatment. Betaloc(0.151 6 g·kg^(-1)·d^(-1)) was used as a positive control. The histopathological analyses of heart in CIH mice were conducted. Several cardiac state parameters, such as left ventricular ejection fractions(EF), stroke volume(SV), expression of creatine kinase(CK), lactate dehydrogenase(LDH), superoxide dismutase(SOD), and malondialdehyde(MDA) were measured. The results showed that treatment with EYQFM markedly reversed swelling of the endothelial cells and vacuolization in the heart when compared with the model group. Further study demonstrated that EYQFM significantly improved ventricular myocardial contractility by increasing EF and SV. In addition, EYQFM inhibited the activity of CK, LDH, decreased the level of MDA and improved SOD activity. The results demonstrated that EYQFM significantly improved the tolerability of myocardium to hypoxia and ameliorated the cardiac damage in the CIH model.展开更多
目的:开展注射用益气复脉(冻干)临床使用合理性再评价真实世界研究。方法:按月份分层随机抽取某医院2020年度1-12月份真实世界注射用益气复脉(冻干)住院病历240份,采用药品说明书评价、药物利用研究(即药物利用指数,drug utilization in...目的:开展注射用益气复脉(冻干)临床使用合理性再评价真实世界研究。方法:按月份分层随机抽取某医院2020年度1-12月份真实世界注射用益气复脉(冻干)住院病历240份,采用药品说明书评价、药物利用研究(即药物利用指数,drug utilization index for dose/concentration, dDUI/cDUI)及药品不良反应监测综合方法,探讨注射用益气复脉(冻干)临床使用合理性再评价问题。结果:注射用益气复脉(冻干)临床使用合理性评价指标给药浓度(22.50%)、给药剂量(27.50%)、中医辨病(28.75%)、中医辨证(43.75%)、溶媒剂量(44.17%)相对不高。药物利用研究提示,注射用益气复脉(冻干)临床给药剂量明显不足(dDUI=0.76<1),而超浓度使用情况严重(cDUI=1.73>1)。此外,药品不良反应监测办公室未收集到2020年度注射用益气复脉(冻干)药品不良反应病例报告;国内有关注射用益气复脉(冻干)药品不良反应文献报道主要涉及心血管系统、神经系统、消化系统、皮肤及其附件。结论:基于当前真实世界证据,应加强该医院注射用益气复脉(冻干)临床监测工作,尤其是超浓度使用、滴定速度以及联合配伍冲管问题。展开更多
基金supported by Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine(No.ZYYCXTD-D-202005)the Key Project at Central Government Level(No.2060302)the Special Project for Transformation of Scientific and Technological Achievements in Qinghai Province(No.2021-SF-150).
文摘The pharmacological studies of Yiqi Fumai lyophilized injection in cardiovascular system mainly include anti-cardiac failure,improvement of myocardial ischemia,improvement of myocardial hypertrophy and myocardial injury caused by ischemia and hypoxia.In recent years,a large number of studies have shown that Yiqi Fumai Lyophilized Injection has good protective effects on myocardial injury caused by ischemia and hypoxia by enhancing myocardial contractility and delaying ventricular remodeling.
基金supported by the National Natural Science Foundations of China(Nos.81274004,81473317)
文摘Yi-Qi-Fu-Mai(YQFM) is extensively used clinically to treat cardiovascular diseases in China. To explore the anti-hypoxia effect of the extract of YQFM preparation(EYQFM), the EYQFM(1.4, 2.8, and 5.5 g·kg-1·d-1) was assessed for its heart-protective effect in a chronic intermittent hypoxia(CIH) animal model(oxygen pressure 7%-8%, 20 min per day) for 28 days of treatment. Betaloc(0.151 6 g·kg^(-1)·d^(-1)) was used as a positive control. The histopathological analyses of heart in CIH mice were conducted. Several cardiac state parameters, such as left ventricular ejection fractions(EF), stroke volume(SV), expression of creatine kinase(CK), lactate dehydrogenase(LDH), superoxide dismutase(SOD), and malondialdehyde(MDA) were measured. The results showed that treatment with EYQFM markedly reversed swelling of the endothelial cells and vacuolization in the heart when compared with the model group. Further study demonstrated that EYQFM significantly improved ventricular myocardial contractility by increasing EF and SV. In addition, EYQFM inhibited the activity of CK, LDH, decreased the level of MDA and improved SOD activity. The results demonstrated that EYQFM significantly improved the tolerability of myocardium to hypoxia and ameliorated the cardiac damage in the CIH model.
文摘目的:开展注射用益气复脉(冻干)临床使用合理性再评价真实世界研究。方法:按月份分层随机抽取某医院2020年度1-12月份真实世界注射用益气复脉(冻干)住院病历240份,采用药品说明书评价、药物利用研究(即药物利用指数,drug utilization index for dose/concentration, dDUI/cDUI)及药品不良反应监测综合方法,探讨注射用益气复脉(冻干)临床使用合理性再评价问题。结果:注射用益气复脉(冻干)临床使用合理性评价指标给药浓度(22.50%)、给药剂量(27.50%)、中医辨病(28.75%)、中医辨证(43.75%)、溶媒剂量(44.17%)相对不高。药物利用研究提示,注射用益气复脉(冻干)临床给药剂量明显不足(dDUI=0.76<1),而超浓度使用情况严重(cDUI=1.73>1)。此外,药品不良反应监测办公室未收集到2020年度注射用益气复脉(冻干)药品不良反应病例报告;国内有关注射用益气复脉(冻干)药品不良反应文献报道主要涉及心血管系统、神经系统、消化系统、皮肤及其附件。结论:基于当前真实世界证据,应加强该医院注射用益气复脉(冻干)临床监测工作,尤其是超浓度使用、滴定速度以及联合配伍冲管问题。
